Claritas Pharmaceuticals, Inc.
Claritas Pharmaceuticals, Inc. (CLAZF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
clazf · pe ratio · data through Dec 31, 2020
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Claritas Pharmaceuticals, Inc. (CLAZF) measures how much investors pay for each dollar of the company's trailing earnings. CLAZF's current PE ratio of 0.00x is calculated by dividing its stock price of $0.00 by its TTM earnings per share of $0.16. −96.8% discount vs 5Y avg 0.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2020-12-31
PE Ratio History
2005 – 2020 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Claritas Pharmaceuticals, Inc.You CLAZF | $0M | 0.00x | — | $0.16 |
 Adcock Ingram Holdings Limited AIHLF | $624M | 7.40x | — | $5.85 |
 Columbia Care Inc. CCHWF | $521M | N/A | — | -$0.26 |
 Opthea Limited CKDXF | $602M | N/A | — | -$0.13 |
 Immune Therapeutics, Inc. IMUN | $8M | N/A | — | -$0.16 |
 Inventiva S.A. IVEVF | $556M | N/A | — | -$1.90 |
 PT Tempo Scan Pacific Tbk PEXXF | $463M | N/A | — | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2020-12-31Latest FY2020 | 0.00x | $0.16 | — | |
2019-12-31 FY2019 | — | $-0.95 | — | |
2018-12-31 FY2018 | 0.04x | $0.55 | — | |
2017-12-31 FY2017 | — | $-5.13 | — | |
2016-12-31 FY2016 | — | $-7.86 | — | |
2015-12-31 FY2015 | — | $-1.92 | — | |
2014-12-31 FY2014 | — | $-0.47 | — | |
2013-12-31 FY2013 | — | $-183.89 | — | |
2012-12-31 FY2012 | — | $-227.05 | — | |
2011-12-31 FY2011 | — | $-209.42 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Claritas Pharmaceuticals, Inc. (CLAZF) measures how much investors pay for each dollar of the company's trailing earnings. CLAZF's current PE ratio of 0.00x is calculated by dividing its stock price of $0.00 by its TTM earnings per share of $0.16.
Frequently asked questions
CLAZF pe ratio · 6 questionsCLAZF's current PE ratio is 0.00x as of 2026-06-08, based on a stock price of $0.00 and TTM EPS of $0.16. Data sourced from Financial Modeling Prep via CLAZF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Claritas Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08